Lilly decision spells end for inhaled insulin
March 12, 2008Research and Development
Regulatory problems and doubts about commercial potential have led Lilly to abandon its late-stage inhaled insulin product. The AIR insulin …
New laws will oblige pharma to release data
March 7, 2008Sales and Marketing
The UK government has pledged to introduce new legislation that will require pharmaceutical companies to disclose all data from clinical …
GPs reluctantly agree to extend hours
March 7, 2008General practitioners across the UK have voted to accept new working hours that will see surgeries open on Saturday mornings …
Efexor successor approved in US
March 7, 2008Sales and Marketing
Wyeth's Pristiq, a refined version of its top-selling depression treatment Efexor, has been approved in the US. Pristiq (desvenlafaxine) delivers …
Renovo wounded by cosmetic drug setback
March 7, 2008Research and Development, Sales and Marketing
UK biotech company Renovo has received disappointing clinical trial results for its new anti-scarring and wound healing drug Juvista. The …
Frontline doctor to lead UK diabetes strategy
March 7, 2008Dr Rowan Hillson has been appointed the new national clinical director for diabetes. Dr Hillson is a consultant physician and …
NICE’s approach to benefits and costs to be reviewed
March 7, 2008Sales and Marketing
The pharmaceutical industry has welcomed plans to review how NICE assesses the benefits and costs of drugs, with the hope …
Diabetes nurses would cut emergency admissions
March 7, 2008Sales and Marketing
Specialist nurses could help to cut the number of diabetes patients being admitted to hospital as emergency cases, a new …
Latest news from Datamonitor
March 5, 2008Sales and Marketing
APP Pharma granted approval for generic anticancer drug APP Pharmaceuticals has received final approval from the FDA of its abbreviated …
Government remains tight-lipped on PPRS
February 29, 2008Sales and Marketing par
The Department of Health has refused to comment on renewed speculation on the future of the UK's medicines pricing system …
FDA rejects long-acting version of Zyprexa
February 29, 2008Sales and Marketing
Lilly has suffered a setback after the US medicines regulator rejected a new version of its top-selling product Zyprexa. The …
Working with NICE: the ingredients for success
February 29, 2008Research and Development, Sales and Marketing NICE, healthcare, industry relations, pharma
NICE fascinates everyone in the industry, and NICE knows only too well that every move it makes is studied by …
Avastin receives surprise FDA approval
February 29, 2008Sales and Marketing
The FDA gone against the advice of its own advisory panel to approve Genentech's Avastin as a first-line treatment for …
AstraZeneca fined $200m over Medicaid pricing
February 29, 2008Sales and Marketing
A US court has ruled AstraZeneca must pay more than $200 million for inflating the prices of drugs prescribed under …
Latest news from Datamonitor
February 28, 2008Sales and Marketing
Algeta to initiate US clinical trials for prostate cancer drug Cancer therapeutics company Algeta has said that it will commence …
GlaxoSmithKline’s Tyverb poised for launch in the UK
February 27, 2008Research and Development
GlaxoSmithKline says its new breast cancer drug Tyverb is ready for launch and could be prescribed to the first UK …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
